NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Price, News & Analysis

Fulgent Genetics logo
$25.13 +0.92 (+3.80%)
Closing price 04:00 PM Eastern
Extended Trading
$25.12 0.00 (-0.02%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Fulgent Genetics Stock (NASDAQ:FLGT)

Advanced

Key Stats

Today's Range
$23.84
▼
$25.49
50-Day Range
$18.66
▼
$26.15
52-Week Range
$13.46
▼
$31.04
Volume
392,967 shs
Average Volume
386,339 shs
Market Capitalization
$702.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Reduce

Company Overview

Fulgent Genetics, Inc. is a diagnostics and therapeutics company that provides genetic testing and other laboratory services. Its offerings include tests for inherited conditions, cancer and infectious diseases, as well as pathology services for healthcare providers and health systems.

Founded in 2011 and headquartered in Temple City, California, the company expanded its diagnostic capabilities through its 2021 acquisition of Inform Diagnostics, a provider of specialized pathology services. Fulgent also conducts research and development focused on precision therapies, including potential cancer treatments.

Founder Ming Hsieh serves as Fulgent Genetics’ chief executive officer. The company serves customers in the United States and participates in international markets through its diagnostic operations.

AI Generated. May Contain Errors.

Fulgent Genetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

FLGT MarketRank™: 
1.51181744091 of 5 stars

Fulgent Genetics scored higher than 30% of companies evaluated by MarketBeat, and ranked 1491st out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fulgent Genetics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Fulgent Genetics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Fulgent Genetics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Fulgent Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fulgent Genetics are expected to grow in the coming year, from ($2.79) to ($2.49) per share.

  • Price to Book Value per Share Ratio

    Fulgent Genetics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.32% of the float of Fulgent Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulgent Genetics has a short interest ratio ("days to cover") of 7.81.
  • Change versus previous month

    Short interest in Fulgent Genetics has recently decreased by 5.40%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Fulgent Genetics does not currently pay a dividend.

  • Dividend Growth

    Fulgent Genetics does not have a long track record of dividend growth.

  • News Sentiment

    Fulgent Genetics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $117,156.00 in company stock.

  • Percentage Held by Insiders

    36.18% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fulgent Genetics' insider trading history.
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FLGT Stock News Headlines

Fulgent: 3 key takeaways for long-term investors
The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
Fulgent Genetics Earnings Call Shows Improving Losses
Fulgent Genetics (NASDAQ:FLGT) Upgraded to "Hold" at Wall Street Zen
See More Headlines

FLGT Stock Analysis - Frequently Asked Questions

Fulgent Genetics' stock was trading at $26.27 on January 1st, 2026. Since then, FLGT shares have decreased by 4.3% and is now trading at $25.13.

Fulgent Genetics, Inc. (NASDAQ:FLGT) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.56. The business had revenue of $90.41 million for the quarter, compared to the consensus estimate of $86.30 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 5.66% and a negative net margin of 27.53%.
Read the conference call transcript
.

The following companies are subsidiaries of Fulgent Genetics: Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC.

Fulgent Genetics (FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics' top institutional shareholders include State Street Corp (1.85%), Goldman Sachs Group Inc. (1.23%), Jump Financial LLC (0.48%) and Caxton Associates LLP (0.47%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Jian Xie and Paul Kim.
View institutional ownership trends
.

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Tesla (TSLA), Trade Desk (TTD), Block (XYZ), Pinterest (PINS) and Appian (APPN).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:FLGT
CIK
1674930
Employees
1,315
Year Founded
2011

Price Target and Rating

High Price Target
$25.00
Low Price Target
$25.00
Potential Upside/Downside
-0.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.51 million
Net Margins
-27.53%
Pretax Margin
-29.97%
Return on Equity
-5.66%
Return on Assets
-5.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.34
Quick Ratio
5.34

Sales & Book Value

Annual Sales
$322.67 million
Price / Sales
2.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$35.24 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
27,940,000
Free Float
17,831,000
Market Cap
$702.13 million
Optionable
Optionable
Beta
1.00

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:FLGT) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners